jCyte Developing Cell-based RP Treatment at Ophthalmology Innovation Summit @ AAO скачать в хорошем качестве

jCyte Developing Cell-based RP Treatment at Ophthalmology Innovation Summit @ AAO

This company has developed a cell-based therapy (jCell) to preserve and restore vision in people with retinitis pigmentosa (RP), although the therapy is potentially applicable to other blinding diseases, as the treatment is nonsurgical and minimally invasive. jCyte is fully funded through its Phase IIb trial through the California Initiative in Regenerative Medicine (CIRN), and the company’s platform was granted breakthrough designation in 2017. Results from a Phase I/IIa trial (n=28) found jCell to be safe and well tolerated; the Phase IIb trial started during Q3 2017 and is actively enrolling. jCell has “extreme efficacy” in RP, said David Boyer, MD, one of the company’s investigators. jCell is human retinal progenitor cells that are not pluripotent; the mechanism of action is neurotrophic (not regenerative or reparative). “jCyte is the only cell therapy program using intravitreal injection of an ocular cell type versus subretinal,” Dr. Boyer said. Waterfall plots showed at six months the majority of patients improved with treatment, and efficacy was between 5 and 10 letters in the 1 million and 2 million cell arms; it trended slightly higher to 10–15 letters in the 3 million cell arm, a trend that continued into 12 months. REGISTER for our next ophthalmology conference today http://bit.ly/2yFA6cv. WEBSITE https://ois.net FOLLOW Ophthalmology Innovation Summit On Social Media: ► Facebook:   / ois.net   ► Twitter:   / oistweets   JOIN Our Group For Ophthalmology Innovation & Investment On LinkedIn   / 2189664   SUBSCRIBE To Our Weekly OIS Newsletter http://bit.ly/2yFOXUt VIEW Our Past Ophthalmology Event Conferences: http://bit.ly/2yJ4Qts REGISTER For Our Next Conference: http://bit.ly/2yFA6cv #jCyte #jCell #blindness #OIS #Ophthalmology #Healthcare _________________________________________________________________ About OIS Ophthalmology Innovation Summit, or OIS for short, facilitates meaningful interactions and the exchange of information between clinical, capital, and corporate leaders to accelerate the development and commercialization of novel therapies to address unmet needs. The Ophthalmology Innovation Summit programs are presented annually by Healthegy, Inc. as affiliate meetings with American Academy of Ophthalmology (AAO), American Society of Cataract and Refractive Surgery (ASCRS), Southeastern Congress of Optometry (SECO), and American Society of Retina Specialists (ASRS). ____________________________________________________________________ Healthegy also is the producer of Aesthetics Innovation Summit (AIS), which unites the clinical, corporate and capital leaders to facilitate the exchange of insights on emerging trends while showcasing exciting new drugs, devices, and technologies for the aesthetics market which is projected to double by 2025. ► Website: https://attendais.com ► Facebook:   / aestheticsinnovationsummit   ► Instagram:   / ais_summit   ► Twitter:   / ais_summit   ► Healthegy Website: https://healthegy.com